Welcome to our dedicated page for Seres Therapeutics SEC filings (Ticker: MCRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Seres Therapeutics, Inc. (MCRB) SEC filings page on Stock Titan provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. These documents include Form 8-K current reports, which Seres uses to announce quarterly financial results, operational updates, leadership changes, cost-reduction actions, and other material events.
For a clinical-stage live biotherapeutics company like Seres, SEC filings are a primary source of information on the status of its programs and financial position. In recent 8-K filings, the company has reported results and updates related to its lead investigational candidate SER-155, including descriptions of Phase 1b data in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT), regulatory designations such as Breakthrough Therapy and Fast Track, and ongoing interactions with the U.S. Food and Drug Administration regarding a planned Phase 2 study design.
Filings also discuss the company’s classification of historical VOWST™ operating results as discontinued operations following the sale of that asset to Nestlé Health Science, as well as the provision of manufacturing services under a Transition Services Agreement. Additional disclosures cover cash runway expectations, workforce reductions, and business development efforts aimed at securing capital or strategic partnerships to advance SER-155 and other live biotherapeutic candidates.
On Stock Titan, these SEC filings are complemented by AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand topics such as trial plans, risk factor discussions, and material corporate actions. Users can review 8-Ks and other filings in real time as they are posted to EDGAR, and use AI-generated insights to interpret how Seres’ regulatory and financial disclosures relate to its live biotherapeutics pipeline and overall strategy.
Seres Therapeutics announced major leadership changes and new pay packages for top executives. The board appointed director Richard N. Kender as Executive Chair and Interim Chief Executive Officer, effective March 2, 2026. Former Co‑CEOs Thomas J. DesRosier and Marella Thorell stopped serving as Co‑Presidents and Co‑CEOs but remain Chief Legal Officer and Chief Financial Officer.
Chief Scientific Officer Matthew Henn adds the role of President, and Kelly Brady becomes Executive Vice President, Chief Operating Officer. Kender will earn a $520,000 base salary, a 55% target bonus, a $250,000 signing bonus, and options on 200,000 shares. Henn’s salary rises to $505,000 with a 45% target bonus, a $230,000 retention bonus, and options on 100,000 shares. Brady’s salary increases to $475,000 with a 45% target bonus, enhanced severance protections, a $230,000 retention bonus, and options on 75,000 shares. Portions of each option grant depend on stockholder approval of an increase to the 2025 Incentive Award Plan at the 2026 annual meeting.
Seres Therapeutics director Eric D. Shaff reported several equity transactions on February 15, 2026 tied to his restricted stock units (RSUs). He exercised RSU-derived rights for a total of 723 shares of common stock, then sold 259 shares of common stock at $8.47 per share under a pre-arranged Rule 10b5-1 instruction, which the filing states was intended solely to cover taxes from RSU vesting. Following these moves, he directly held 11,577 shares of common stock, while his RSU awards continue to vest in scheduled quarterly installments.
Seres Therapeutics officer Teresa L. Young reported multiple Form 4 transactions involving restricted stock units and common stock. She acquired 231 shares of common stock on
Seres Therapeutics, Inc. officer Thomas DesRosier reported routine equity compensation activity and a small share sale. On February 15, 2026, he acquired common stock through the exercise and settlement of restricted stock units, then sold 78 shares of common stock at
Seres Therapeutics, Inc. officer Matthew R. Henn reported RSU vesting and related share movements. On February 15, 2026, he acquired 141 and 98 shares of common stock through the exercise and settlement of restricted stock units, plus another 239 shares, and then sold 89 common shares at
Seres Therapeutics (MCRB)November 15, 2025, receiving 3,998, 132, and 98 shares in three separate transactions. On the same date, she sold 1,042 shares of common stock at a price of $17.30 per share, and held 8,401 shares directly after the reported transactions. The filing notes the sales were made under a pre-arranged Rule 10b5-1 trading instruction adopted on March 5, 2023, with the stated purpose of covering taxes related to RSU vesting.
Seres Therapeutics, Inc. director reports RSU vesting and small share sale. On 11/15/2025, the reporting person exercised restricted stock units that converted into 390 and 331 shares of common stock, increasing direct holdings and reflecting ongoing equity compensation. On the same date, 217 shares of common stock were sold at $17.30 per share under a pre-arranged Rule 10b5-1 trading instruction intended solely to cover taxes tied to the RSU vesting. After these transactions, the director directly beneficially owned 11,113 shares of common stock, along with 1,954 and 2,989 restricted stock units that vest in scheduled quarterly installments.
Seres Therapeutics, Inc. (MCRB) reported insider equity activity by its Chief Legal Officer, EVP, Co-Chief Executive Officer, and Co-President on 11/15/2025. The filing shows the exercise and settlement of restricted stock units into 132 shares and 112 shares of common stock, each RSU granting one share upon vesting. On the same date, 76 shares of common stock were sold at $17.30 per share under a Rule 10b5-1 trading instruction adopted on March 2, 2023, solely to cover taxes tied to RSU vesting. After these transactions, the reporting person directly owned 7,623 shares of common stock and retained 664 and 1,001 restricted stock units, which vest in scheduled quarterly installments and have no expiration date.
Seres Therapeutics (MCRB)November 15, 2025, several blocks of restricted stock units (RSUs) were converted into common stock, including 3,998, 140, and 98 shares. After these transactions and a sale, Henn held 7,527 shares of common stock directly.
The filing shows a sale of 1,257 shares of common stock at $17.30 per share. According to the explanation, these sales were made under a pre-arranged Rule 10b5-1 instruction adopted on April 13, 2023, and were executed solely to cover taxes arising from RSU vesting. The RSUs vest over time in scheduled installments, with certain awards having no expiration date and vesting quarterly after initial 25% vesting dates.
Seres Therapeutics (MCRB) reported Q3 2025 results. The company posted net income from continuing operations of $8.2 million for the quarter, driven by a $27.2 million gain on sale related to the VOWST business and $2.8 million of other income that included TSA reimbursements, against $22.8 million of operating expenses. Grant revenue was $351 thousand in Q3 2025, reflecting a CARB-X award tied to SER-155 development.
For the nine months ended September 30, 2025, net income from continuing operations was $21.0 million, including a year‑to‑date $79.6 million gain on the VOWST sale. Cash and cash equivalents were $47.6 million as of September 30, 2025, and total stockholders’ equity rose to $43.7 million from $13.8 million at year‑end 2024. The company disclosed substantial doubt about its ability to continue as a going concern based on current cash resources and forecasted operations.
Seres is advancing SER‑155, supported by a CARB‑X grant of up to $3.6 million, and recorded $1.0 million of restructuring costs tied to a ~25% workforce reduction announced on September 23, 2025. Shares outstanding were 8,764,664 as of September 30, 2025, and 9,046,519 as of October 31, 2025.